KeyPath™ MRSA/MSSA Blood Culture Test
Download this product sheet |
The KeyPath™ MRSA/MSSA Blood Culture Test enables clinicians to optimize therapy by identifying and determining methicillin resistance or susceptibility of Staphylococcus aureus directly from Gram-positive blood cultures in five-and-a-half hours – one, two, or more days faster than standard AST testing. Despite the medical community's best efforts, fatality rates are increasing largely due to antibiotic resistance. Current diagnostic methods require 48 to 72 hours – more time than is clinically permissible – meaning physicians often base treatments on their experience rather than individual patient data. MicroPhage's bacteriophage amplification platform enables early identification of S. aureus and determination of methicillin resistance (MRSA) or methicillin susceptibility (MSSA) to deliver actionable results when clinicians need them. Simple to perform without the need for expensive equipment, MicroPhage is making high-value diagnostics accessible to all institutions, large and small. |
Benefits of MicroPhage KeyPath™ Bacterial Identification and Antibiotic Susceptibility Testing
- Key pathogen results one to two days faster than current methods
- True Phenotypic AST results for confidence
- Facilitates earlier optimization of antimicrobial therapy
- Better patient outcomes, decreased hospital length of stay, cost-effective
- Simple – requires no special equipment or training
The Case for Accelerated Susceptibility Testing in the Era of Antibiotic Resistance Whitepaper. Click here to download.
|
Powerful knowledge – in time to save lives.
1 Pfaller et al. J. Antimicrob. Agent. Chemother. (42): 1762-1770.
This test is both FDA-cleared and CE marked for sale within and outside the U.S.